Passage bio ipo (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Passage Bio Cutting 55% of Staff to Help Extend Cash Runway. The company issued 7,400,000 shares at $16. Passage Bio’s lead Passage Bio (Nasdaq: PASG) ha riportato i risultati finanziari e le principali novità aziendali del secondo trimestre 2024. All Rights Reserved. This gene-therapy biotech closed on February 24, 2023, at $1. 04, 2020. Bigshare Services Pvt Ltd. This page was last refreshed on Friday at 07:47 PM ET. Overview; Frontotemporal Dementia; Patients and Caregivers. With the IND on clinical hold, Passage Bio now expects to dose the first patient in the fourth quarter of 2020 or first quarter of 2021. See the company profile for Passage Bio, Inc. The Philadelphia, PA-based company now plans to raise $170 million by offering 10 About Passage Bio. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, I survey Passage Bio and its programs to find reasons to monitor its progress with the potential of investing in the future. Stay ahead with Nasdaq. Passage Bio has filed to raise $126 million in an IPO of its common stock. The IPO took place during a quiet week for exits, amid an IPO slump and coronavirus PHILADELPHIA, Jan. 14, 2020 2 Comments. Includes open, high, low, close and volume. Market sentiment may be different from the days when an extensive gene therapy pipeline Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference. The issue is priced at ₹123 to ₹130 per share. Following this success, Passage Bio filed for a $216M IPO in February 2020; Chardan acted as lead manager. Please note that any opinions, estimates or forecasts regarding Passage Bio, Inc. , a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced the pricing of its initial public offering of 12,000,000 shares of common stock at a public offering price of $18. The issue is priced at ₹113 to ₹119 per share. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an initial public offering on Friday, February 28th 2020. Paragon Wholesale Foods Corp. All State & Fed. SEC Filings. Operating within the biotechnology and pharmaceutical industry, Passage Bio caters to the At Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions. 00 (-4. At Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions. 6 days ago - Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates - GlobeNewsWire 2 months ago - Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire 3 months ago - Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD About Passage Bio . © Passage Bio. 866. Passage Bio (NASDAQ:PASG) has filed to raise $125 million in an IPO of its common stock, according to an S-1 registration statement. , president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on View SEC filing statements and past annual reports. Strong sell . Passage Bio has few drug candidates in its pipeline including three that should begin Phase 1/2 studies soon. On what stock exchange are Passage Bio’s shares traded, and what is the ticker? Passage Bio stock is traded on the Nasdaq Global Select Market under the ticker PASG. The firm is a pre-clinical biopharma working on monogenic treatments for central nervous system disorders. Toppy v. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. Shubhshree Biofuels Energy IPO is a SME IPO of 1392000 equity shares of the face value of ₹10 aggregating up to ₹16. Super. Advancing Lead Clinical Programs in Neurodegenerative Diseases. The amount raised is more than the combined total of the region's last four life sciences IPOs. With the new round of layoffs, PASG News. 10, 2024 (GLOBE NEWSWIRE) - Passage Bio, Inc. This public offering provided the necessary capital to advance clinical trials for their pipeline of gene therapies. What is Passage Bio's forecast for 2025? According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price PHILADELPHIA, Sept. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the appointment of Athena Countouriotis to its board of directors. The expanded deal includes Passage providing annual $5 payments to support gene therapy research at Penn. Venture At Passage Bio, we believe that collaboration is an important component of transformation, and we are committed to working with patient advocacy groups that are also committed to transforming lives. , president and chief executive officer, will present at Chardan’s 8 th Annual Genetic Medicines Conference on Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed View press releases and financial reports for Passage Bio. Unbeknownst to Appellant at that time, Appellee already intended to authorize a pre-IPO reverse split of its Launching an initial public offering (IPO) the same week the stock market plunged 1,190 in a single day may just be bad luck, but it doesn’t seem to have negatively affected Passage Bio’s IPO. Browne was an Executive 02/27/2024 - 07:00 AM . 5M over 4 rounds. Recent area biotech IPOs include Malvern-based Tela Bio Inc. 2024. The 13% staff reduction represented about 17 Penn gene therapy spinout Passage Bio exceeded projections with a $216M IPO on Friday. The firm is developing genetic treatments for Passage Bio (NASDAQ: PASG) is a genetics medicine company founded in 2017 and headquartered in Philadelphia, Pennsylvania. Learn more about PASG stock here. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M. Who is Passage Bio’s transfer agent? Does Passage Bio have a direct stock purchase plan? Who are Passage Bio’s legal counsel and independent auditor? How can I get the latest corporate news and financial reports? Who should I contact if I have a question or request about Passage Bio? How can I obtain a copy of your annual report and proxy? Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases. 20 but fell to $21. A. For further information, please contact: Passage Bio Investors: Stuart Henderson Passage Bio 267-866-0114 shenderson At Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. 06, 2021 Passage Bio upgraded to buy from neutral at Goldman Sachs Gene therapy manufacturing is a critical factor in the successful development and commercialization of novel genetic medicines. The minimum order quantity is . Common Stock (PASG) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Citing Cases. Medtech Insight. Passage Bio expects to report 30-day safety and biomarker data late in the first half of 2021. Our Approach; Role of Progranulin; Manufacturing; Pipeline. 2024 2023 2022 2021 2020. is followed by the analysts listed above. Passage Bio To IPO Soon, Promising Gene Therapy Pipeline Against Rare Diseases Terry Chrisomalis Fri, Feb. (PASG) with real-time updates, full price history, technical analysis and more. Get a complete stock price history for Passage Bio, starting from its first trading day. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,000,000 PriceRange: $18 Discount Per Get the latest Passage Bio Inc (PASG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 6 mil (last 12 months) IPO Profile: Symbol: PASG: Exchange: NASDAQ: Shares (millions): from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. Morgan, Goldman Passage Bio, Inc. Passage Bio’s lead About Passage Bio. , a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous Passage Bio, Inc. Manager Portfolios. The company plans to amend the ongoing Phase 1/2 global study protocol to introduce this new patient population, with dosing expected to begin in 1H 2025. View the latest quarterly presentation. The reduction will impact 25 employees. Passage Bio (NASDAQ:PASG) had its IPO in 2019 at over $20. Home. In addition to gangliosidosis, the company has two other candidates in the clinic, one for Krabbe disease and the other for Discover Passage Bio’s gene therapy pipeline for rare disorders of the central nervous system, including 3 therapies in Phase 1/2 clinical trials. Mr. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that additional clinical and biomarker data from Cohort 1 in the Imagine-1 study for GM1 gangliosidosis will be presented at the In March, Passage Bio cut its workforce and narrowed its research and development focus to extend its cash runway into the second quarter of 2024. Passage Bio stock is expected to receive a positive boost from a couple of triggering events ahead. . (PASG) latest earnings report: revenue, EPS, surprise, history, news and analysis. Make informed investments with Nasdaq. At the midpoint of the proposed range, Passage Bio would command a fully diluted market value of $713 million. Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. back to top. I punti salienti includono: Inizio della registrazione del primo paziente FTD-GRN nel Coorte 2 dello studio upliFT-D; L'FDA ha acconsentito ad ampliare lo studio upliFT-D per includere pazienti FTD-C9orf72 Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Passage Bio is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Maashitla Securities Private Limited. (PASG) CEO Bruce Goldsmith on Q2 2020 Results Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with longest follow-up Completed dosing of Cohort 1 (n=5) in upliFT-D trial; on track to deliver 6-month safety and biomarker data from Cohort 1 in 2H 2024 Plan to continue Frazier Lifesciences Acquisition, a blank check company formed by Frazier Healthcare Partners targeting the biotech industry, filed on Friday with the SEC to raise up to $100 million in an initial Passage Bio plans to support lab operations for its gene therapy programs at a new lab at the Princeton West Innovation Campus. We have established manufacturing and global clinical distribution that support our pipeline from lab Find recent and upcoming investor events for Passage Bio. Passage BIO: Financial Information: Market Cap: $792. Passage Bio intends to raise $125 million in an upcoming IPO. Passage Bio (PASG) stock soars as the company out-licenses gene therapy programs targeting pediatric lysosomal storage diseases to GEMMA Biotherapeutics. Pink Sheet. Start Free Trial . Finance Watch: Coronavirus-Related Stock Get real-time updates on Passage Bio, Inc. com. Also, RedHill raised $115m for product launches and Movantik purchase, and Avadel raised $65m to compete with Jazz. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. 00 Biotech firm Passage Bio, which develops gene therapies for rare central nervous system disorders, went public on February 28. FierceBiotech — After bagging $200M-plus in 2019, Passage Bio guns for $125M IPO . 00 per share. This expansion is supported by compelling preclinical Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS). The IPO took place during a quiet week for exits, amid an IPO slump and coronavirus Our vision is to become the premier genetic medicines company by developing and ultimately commercializing therapies that dramatically and positively transform the lives of patients Discover real-time Passage Bio, Inc. D. Public Company Edition: The gene therapy firm’s IPO priced at $18 and ended its first day up 23. Who is Passage Bio’s transfer agent? Computershare Trust Company, N. 06, 2024 (GLOBE NEWSWIRE) - Passage Bio, Inc. The IPO opens on November 26, 2024, and closes on November 28, 2024. Passage Bio (PASG) shares surged 9% on encouraging Phase 1/2 data for gene therapy candidate PBFT02 in treating FTD-GRN, a type of early onset dementia. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript SA Transcripts Tue, Nov. The company, which went public in the local life sciences industry's largest IPO in 2021, said Thursday it is reducing its headcount by roughly 23% to lower operating expenses. Discover Passage Bio’s gene therapy pipeline for rare disorders of the central nervous system, including 3 therapies in Phase 1/2 clinical trials. Genetic drug development is especially difficult for neurodegenerative disorders due to challenges in crossing the blood-brain barrier and the potential off-target effects. Passage Bio's latest post-money valuation is from February 2020. We are looking for innovators who are passionate about delivering life-transforming therapies to people with CNS disorders. stock was issued. The company is looking to initiate dosing for its PBGM01 Phase 1/2 trial in late 4Q2020 or early Passage Bio, an early stage biotech developing therapies for monogenic CNS disorders, filed on Monday with the SEC to raise up to $125 million in an initial public offering. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 10, 2020 Passage Bio, Inc. At Passage Bio, our culture revolves around people—those we serve and those who are helping us change the world. Detailed balance sheet for Passage Bio (PASG), including cash, debt, assets, liabilities, and book value. Passage Bio was founded in 2017 and plans to list on the Nasdaq under the symbol PASG. 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. Passage Bio has raised $225. The Philadelphia, PA-based company now Interactive stock price chart for Passage Bio, Inc. 03%) More news for this symbol. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that the first patient has been dosed in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus PHILADELPHIA , Nov. 1000. Funding, Valuation & Revenue. Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, increased the proposed share offering for its upcoming IPO on Thursday. 3% at $22. Passage Bio (NASDAQ: PASG) has received positive feedback from the FDA on expanding its upliFT-D trial of PBFT02 to include FTD-C9orf72 patients. The lab will be the company’s second manufacturing facility Passage Bio, Inc. (PASG) SEC Filing S-1 IPO report for the period ending Saturday, August 29, 2020. Now, the gene therapy PHILADELPHIA, Jan. Passage Bio is studying a potential genetic medicine for people with FTD-GRN in a clinical trial called upliFT-D. Insider Trades. 00 per share and then hit a peak at $36. The IPO opens on September 9, 2024, and closes on September 11, 2024. Our Passage Bio (NASDAQ: PASG) has leased about 62,000 square feet of lab space at the campus, which is intended to support analytics, process development, quality control and pilot manufacturing. Wilson, MD, PhD, has disclosed plans to raise $125 million through At Passage Bio, we believe that collaboration is an important component of transformation, and we are committed to working with patient advocacy groups that are also committed to transforming lives. People with FTD The Philadelphia, PA-based company plans to raise $126 million by offering 7. 17 per share. We would like to connect with patients and caregivers through patient advocacy groups to learn more about their journeys and how we can assist them. 4 million shares at a price range of $16 to $18. 0mil: Revenues: $0 mil (last 12 months) Net Income $-45. View daily, weekly or monthly format back to when Passage Bio, Inc. Our approach involves developing cutting-edge, one-time treatments that can alter the course of neurodegenerative diseases and are underpinned by rigorous scientific research and state-of Launching an initial public offering (IPO) the same week the stock market plunged 1,190 in a single day may just be bad luck, but it doesn’t seem to have negatively affected Passage Bio ’s IPO. 19, 2021 (GLOBE NEWSWIRE) - Passage Bio, Inc. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,000,000 Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, raised $216 million by offering an upsized 12 million shares at $18, the high end of Does Passage Bio have a direct stock purchase plan? Who are Passage Bio’s legal counsel and independent auditor? How can I get the latest corporate news and financial reports? Launching an initial public offering (IPO) the same week the stock market plunged 1,190 in a single day may just be bad luck, but it doesn’t seem to have negatively affected Biotech firm Passage Bio, which develops gene therapies for rare central nervous system disorders, went public on February 28. Passage Bio Files Initial Plan For IPO Donovan Jones Tue, Feb. Share your Passage Bio is looking to raise up to $125 million in gross proceeds via an IPO of common shares. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares Summary. Dr. 0114 shenderson@passagebio. Passage Bio (NASDAQ: PASG) started the year with 133 employees, but cut its staff by 13% in March to conserve cash. 's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Quick Take. J. Passage Bio’s lead Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. Who We Are; Our Team; Our Science. Our primary focus is the development and advancement of cutting-edge, one-time therapies About Passage Bio . PASG Valuations. Browne has extensive experience in drug discovery and development for neurological disorders, with particular focus on neurodegenerative, neuropsychiatric, and rare diseases. Media: Initial Public Offering (IPO) Passage Bio went public on October 18, 2019, trading on the NASDAQ under the ticker symbol PASG. PHILADELPHIA, Feb. Passage Bio’s lead product candidate, PBFT02, seeks to treat PHILADELPHIA, Aug. , a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. Share: Previous Post Mission Bio raises The information on this website is intended for use by US residents only. Scrip. (PASG) S-1 IPO Report Mon Feb 03 2020; SEC Filings. Summary. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Our approach involves developing Discover historical prices for PASG stock on Yahoo Finance. 50 when stocks recovered on 2 March. P. Our Phase 1/2 Study in Frontotemporal Dementia (FTD) Passage Bio, Inc. 1200. The IPO raised around $200 million, offering 12 million shares at a price of $17 per share. 07 in June 2021. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced it PASG: 10. Passage Bio finished 2019 with nearly $160 million in the bank but wasted no time coming back for more, filing earlier this month to raise $125 million in its IPO. The company specializes in developing therapeutics for disorders of the central nervous system, with a primary focus on gene therapy. This genetic medicine is intended to deliver a functional GRN gene to elevate levels of PGRN in the brain. 21, 2021 (GLOBE NEWSWIRE) - Passage Bio, Inc. For further information, please contact: Passage Bio Investors: Stuart Henderson Passage Bio 267-866-0114 shenderson . Brian Orelli, PhD | Feb 28, 2020 The clinical-stage biotech raised $216 million. 70 Crores. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager. Read more here. Our Commitment; Compassionate Use Statement; Community Resources; Investors and News. Intrinsic Value. Viancourt v. Company Name: Therapeutic Focus; Treatment Type: Underwriters: IPO Date: Offer Price to the Public: Passage Bio, Inc. The opportunity arose for Chardan to execute this transaction due to its extensive work in the gene therapy sector and strong relationship with early-stage genetic medicine investors. The company filed for a $125 million IPO, which will bankroll the Interactive stock price chart for Passage Bio, Inc. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna Since being promoted to Managing Director in 2014, Tom has assumed the lead role in multiple investments that also have reached liquidity including Crispr (2016 IPO), Audentes (2016 IPO), Annapurna (merged to form Adverum), Gritstone (2018 IPO), Crinetics (2018 IPO), Jecure (sale), Therachon (sale), Aligos (2020 IPO), Passage (2020 IPO), Tempest (2021 reverse merger) Discover Passage Bio’s gene therapy pipeline for rare disorders of the central nervous system, including 3 therapies in Phase 1/2 clinical trials. (NASDAQ: PASG), a clinical stage genetic Passage Bio, Inc. PHILADELPHIA , Nov. 23, 2024 (GLOBE NEWSWIRE) - Passage Bio, Inc. Passage Bio pulls off $216M IPO, blowing past original goal. Learn more about our company. Skip to main content. Sign up for a free demo to see Passage Bio's valuations in February 2020 and more. Passage Bio’s lead product candidate, PBFT02, Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) - Passage Bio, Inc. Passage Bio is exploring genetic medicines that work by delivering functional therapeutic genes to patients with diseases where genes are mutated, nonfunctional, or missing. The company went IPO on 2020-02-28. 56 Crores. About Passage Bio . See upgrades, downgrades, price targets and more from top Wall Street stock analysts. 62% of the company's shares, Since its IPO on February 28, 2020, At Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their conditions. is the registrar for the IPO. Financial Ratios. Our approach involves developing cutting-edge, one-time treatments that can alter the course of neurodegenerative diseases and are underpinned by rigorous scientific research and state-of PHILADELPHIA, Sept. The Philadelphia, PA-based company now A list of analyst ratings for Passage Bio (PASG) stock. January 13, 2025 · 99 min read · Metsera Moves Fast in Crowded Obesity Market With IPO Plans. Opinion Case details. Passage Bio, a developer of gene therapies for rare monogenic CNS diseases whose co-founders include pioneer researcher James M. For further information, please contact: Investors: Stuart Henderson Passage Bio 267. January 13, 2025 · 1 min read · Angela Gabriel. 00-$18. Financial Stability. Y-mAbs, Generation Bio Join Growing List of Companies Cutting Staff. Sionna, Odyssey Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. Prior to joining Passage, Dr. Passage Bio’s lead Passage Bio Stock (NASDAQ: PASG) stock price, news, charts, stock research, profile. Layoff Tracker. 190, see flags on bad law, and search Casetext’s comprehensive legal database. Common Stock (PASG) stock quotes, trades, and more. Get the latest information about the Passage Bio stock price and stock performance over time. (PASG) stock price, news, historical charts, analyst ratings and financial information from WSJ. Despite this reduction, Orbimed Advisors LLC maintains a substantial position in Passage Bio, holding 12. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, Real time Passage Bio (PASG) stock price quote, Gene Therapy Biotech Passage Bio IPOs. passage bio, inc. , 2022 Pa. View press releases and financial reports for Passage Bio. Passage Bio, Inc. It develops PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, Detailed statistics for Passage Bio, Inc. The Barchart Technical Opinion rating is a 100% Sell with a Strongest Rajputana Biodiesel IPO is a SME IPO of 1900000 equity shares of the face value of ₹10 aggregating up to ₹24. Philadelphia-based Passage Bio plans to raise as much as $125 million selling stock shares to the public through an initial public offering (IPO), the Philadelphia-based firm told the Securities and Exchange Commission in a public filing Monday. The Philadelphia-based biotech company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expectedoriginally expected About Passage Bio . Merits a small "watch item" position within a well-diversified biotech portfolio About Passage Bio’s Huntington Disease and Canavan Disease Programs. Despite pulling off two megarounds in 2019, Passage Bio is returning to the funding well—but this time, it’s going public. The main clinical program involves PBGM01, which is being used to treat GM1 gangliosidosis, and a phase 1/2 study will be Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. JX. 4 Fundings. Since joining Passage Bio in June 2021 she has served as our VP of Biology and Head of Biomarkers and Precision Medicine. Passage Bio’s lead Passage Bio is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. The Philadelphia, PA Passage Bio, a preclinical biotech developing gene therapies for rare CNS disorders, raised $216 million by offering an upsized 12 million shares at $18, the high end of the range of $16 to $18. January 13, 2025 · 2 min read · Tristan Manalac. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. , a genetic medicines company focused on developing transformative therapies for rare, February 27, 2020 19:24 ET | Source PHILADELPHIA, Feb. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã -gal) for infantile gm1; pbft02, which utilizes an Passage Bio files for common stock offering up to $125M and mixed shelf offering SA News Sat, Mar. , which raised $52 million last month; Malvern-based radiation-sickness therapy developer Galera Therapeutics, which raised $60 million in its IPO last fall; T-cell immunotherapy developer Cabaletta Bio of Philadelphia, which raised $75 million in its IPO earlier last year; and View SEC filing statements and past annual reports. IPO. Kassberg is currently Chief About Passage Bio . It is trading on the Nasdaq Passage Bio, a gene therapy firm founded by University of Pennsylvania scientist James Wilson, plans to raise $125 million in an initial public offering. , a genetic medicines company, develops gene therapies for central nervous system diseases. About Passage Bio. Sign In. Passage Bio, a James Wilson-founded gene therapy startup, raised two private megarounds last year and completed a $216 million IPO in February, giving it the means to advance a pipeline led by its Find recent and upcoming investor events for Passage Bio. Huntington’s Disease – Passage Bio and GTP have initiated a pre-clinical research program to pursue in parallel multiple approaches for targeting the mutated huntingtin protein (HTT) and the unstable genetic repeat expansion to identify an optimal clinical candidate for the treatment of Preclinical biotech Passage Bio increases IPO share offering by 35%, now plans to raise $170 million February 27, 2020. When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an initial public offering on Friday, February 28th 2020. (PASG) stock, including valuation metrics, financial numbers, share information and more. Our Company. Barchart Technical Opinion. has completed an IPO in the amount of $216 million. The Philadelphia-based biotech company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expected. (PASG) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their PHILADELPHIA, March 05, 2020 (GLOBE NEWSWIRE) - Passage Bio, Inc. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. Search Crunchbase. At the time of its IPO filing, Passage Bio planned to start the phase 1/2 trial in the second half of 2020. Passage Bio's latest funding round was a IPO for $216M on February 28, 2020. Find recent and upcoming investor events for Passage Bio. Since formally launching in February 2019 The Company completed its IPO in February 2020. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Passage Bio, Inc. IPO News for Passage Bio US IPO Week Ahead: Chinese EV's billion-dollar deal closes out summer in a 2 IPO week 08/21/20; No trial, no problem: Biggest week for preclinical biotech IPOs ever 06/09/20; US IPO Week Ahead: The IPO market shutdown continues with Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust Passage Bio, Inc. Our current clinical program utilizes View the latest Passage Bio Inc.
fmcc dptj ypayt itf xhpmm svgopy hcqx hgierda glyua ryw